Aktiesnakken — Juni 2010
-
-
På baggrund af analysen hæver vi sandsynligheden
for at Zalutumumab godkendes i hovedhalskræft
fra 25% til 80%, vi forventer fortsat markedslancering i
2012, og vi hæver desuden vores peaksale fra 1,0 mia.
kr. til 1,5 mia. kr. Herefter viser vores opd -
Herefter viser vores opdaterede NPVmodel
en fair value for Genmab på 123 kr. pr. aktie.
Peter Aabo, BiotekAnalyse.dk -
sådan pepaoter
-
så skal vi nok op kortsigtet på mandag
-
det trænger vi også til
-
AktieUgebrevet 3 ugers prøveperiode
GRATIS! http://www.aktieugebrevet.dk/tilmelding?c=Gratis+Pr�veperiode -
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind